Partnerships Picks For GeNeuro’s MS Antibody
GeNeuro’s CEO And His Mission To Bring Anti-HERV Benefits To MS Patients
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
You may also be interested in...
GeNeuro and partner Servier voiced disappointment over results seen midway through a Phase IIb trial studying a potential cause of multiple sclerosis - but insisted the trial will continue for the final 6 months.
Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.
The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.